This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Remák E, Mullins CD, Akobundu E, Charbonneau C, Woodruff K.Economic evaluations of sunitinib versus interferon-alfa in first-line metastatic renal cell carcinoma. Journal of Clinical Oncology 25 (Suppl.): 348 (plus poster) abstr. 6607, No. 18, Part 1, 20 Jun 2007
Rights and permissions
About this article
Cite this article
Sunitinib cost effective for renal cancer. Pharmacoecon. Outcomes News 532, 8 (2007). https://doi.org/10.2165/00151234-200705320-00016
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705320-00016